Related references
Note: Only part of the references are listed.Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL
Yaqi Zhao et al.
BLOOD (2021)
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
Ling Song et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Translating gammadelta (gamma delta) T cells and their receptors into cancer cell therapies
Zsolt Sebestyen et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
Matthias Klinger et al.
CANCER RESEARCH (2020)
Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).
Horst-Dieter Hummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CAR T cells: continuation in a revolution of immunotherapy
Anurag K Singh et al.
LANCET ONCOLOGY (2020)
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors
Caroline E. Porter et al.
MOLECULAR THERAPY (2020)
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Patrick J. Engelberts et al.
EBIOMEDICINE (2020)
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Cristina Perez et al.
BLOOD (2020)
First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
Joseph Chao et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Keisuke Yamamoto et al.
NATURE (2020)
Human chimeric antigen receptor macrophages for cancer immunotherapy
Michael Klichinsky et al.
NATURE BIOTECHNOLOGY (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
Zong Sheng Guo et al.
BIOMEDICINES (2020)
Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
B. Tran et al.
ANNALS OF ONCOLOGY (2020)
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Luke Coyle et al.
LEUKEMIA & LYMPHOMA (2020)
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
LEUKEMIA & LYMPHOMA (2020)
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
Franco Locatelli et al.
BLOOD CANCER JOURNAL (2020)
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Andras Heczey et al.
NATURE MEDICINE (2020)
Point mutation inCD19facilitates immune escape of B cell lymphoma from CAR-T cell therapy
Zhen Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Kodandaram Pillarisetti et al.
BLOOD ADVANCES (2020)
Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer
Julie M. Bailis et al.
CANCER RESEARCH (2020)
Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
Nicholas J. Short et al.
BLOOD (2020)
Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts
Matthew J. Matasar et al.
BLOOD (2020)
Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
Ibrahim Aldoss et al.
BLOOD (2020)
Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
Sarit E. Assouline et al.
BLOOD (2020)
Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma
Cesar Rodriguez et al.
BLOOD (2020)
Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Adam D. Cohen et al.
BLOOD (2020)
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Simon J. Harrison et al.
BLOOD (2020)
Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Alexander M. Lesokhin et al.
BLOOD (2020)
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Deepu Madduri et al.
BLOOD (2020)
Natural Killer Cells in Immunotherapy: Are We Nearly There?
Mireia Bachiller et al.
CANCERS (2020)
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
Rajat Bannerji et al.
BLOOD (2020)
A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ajai Chari et al.
BLOOD (2020)
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Alfred L. Garfall et al.
BLOOD (2020)
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
Martin Hutchings et al.
BLOOD (2020)
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma
Martin Hutchings et al.
BLOOD (2020)
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia
Priyanka Nair-Gupta et al.
BLOOD ADVANCES (2020)
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
Lan Wu et al.
NATURE CANCER (2020)
Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
Anthony S. Stein et al.
ANNALS OF HEMATOLOGY (2019)
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
Delong Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies
Ping-Pin Zheng et al.
TRENDS IN IMMUNOLOGY (2019)
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss
Ali Bukhari et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson et al.
NATURE IMMUNOLOGY (2019)
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
Michael Friedrich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Functional diversification of IgGs through Fc glycosylation
Taia T. Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion
Harbani Malik et al.
BLOOD (2019)
Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
Deborah A. Katz et al.
BLOOD (2019)
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Krish Patel et al.
BLOOD (2019)
Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Amber C. King et al.
BLOOD (2019)
Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia
Shaun Fleming et al.
BLOOD (2019)
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Noopur S. Raje et al.
BLOOD (2019)
Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Guillaume Richard-Carpentier et al.
BLOOD (2019)
Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias
James K. McCloskey et al.
BLOOD (2019)
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse
Koji Sasaki et al.
BLOOD (2019)
Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504
Marc Schwartz et al.
BLOOD (2019)
Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia
Gregorio Campos-Cabrera et al.
BLOOD (2019)
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach et al.
NATURE (2019)
ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
Mark A Rosenthal et al.
NEURO-ONCOLOGY (2019)
Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency
Linlin Wang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
Eleanor M. Scott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph plus ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial
Sabina Chiaretti et al.
BLOOD (2019)
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Marion y Subklewe et al.
BLOOD (2019)
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Peter Westervelt et al.
BLOOD (2019)
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Luciano J. Costa et al.
BLOOD (2019)
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Vera Dufner et al.
BLOOD ADVANCES (2019)
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
Renee C. G. de Bruin et al.
ONCOIMMUNOLOGY (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Bispecific antibody based therapeutics: Strengths and challenges
Archana Thakur et al.
BLOOD REVIEWS (2018)
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Colin E. Correnti et al.
LEUKEMIA (2018)
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Paul A. Moore et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia
Matthew J. Oberley et al.
PEDIATRIC BLOOD & CANCER (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia
Kristina Klupsch et al.
CANCER RESEARCH (2018)
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
Joshua D. Freedman et al.
CANCER RESEARCH (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
Blinatumomab plus Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience
Marie-Anne Couturier et al.
BLOOD (2018)
Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study
Jonathan Webster et al.
BLOOD (2018)
Development of a Bifunctional Checkpoint Inhibitory T Cell Engager (CiTE) to Reverse Adaptive Immune Escape in AML
Monika Herrmann et al.
BLOOD (2018)
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma
Hui Yu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Liqin Liu et al.
CLINICAL CANCER RESEARCH (2017)
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
Alec J. Walker et al.
MOLECULAR THERAPY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Rita Assi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia
Ibrahim Aldoss et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models
Liat Izhak et al.
CANCER RESEARCH (2017)
Phase Ia and lb studies of the novel carcinoembryonic antigen (CEA) 1-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Hoelzer et al.
ANNALS OF ONCOLOGY (2016)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions
Matthias Klinger et al.
IMMUNOLOGICAL REVIEWS (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernandez-Hoyos et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
Joerg U. Schmohl et al.
MOLECULAR THERAPY (2016)
Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy
Ahmad Rayes et al.
PEDIATRIC BLOOD & CANCER (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
Noelle V. Frey et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
A quantitative systems pharmacology (QSP) model to assess the action of blinatumomab in NHL patients (pts)
Theresa Yuraszeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
Uwe Reusch et al.
MABS (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
G. S. Laszlo et al.
BLOOD CANCER JOURNAL (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells
Keisuke Watanabe et al.
JOURNAL OF IMMUNOLOGY (2015)
Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Hong Xu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system
C. Arndt et al.
LEUKEMIA (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
Hui K. Gan et al.
FEBS JOURNAL (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Piecing together the family portrait of TCR-CD3 complexes
Michael S. Kuhns et al.
IMMUNOLOGICAL REVIEWS (2012)
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage et al.
NATURE (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-1BB Ligand/Anti-CD20 Fusion Proteins and Anti-CD3/Anti-CD20 Diabodies
Rong Liu et al.
JOURNAL OF IMMUNOTHERAPY (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique
P. Mhawech-Fauceglia et al.
HISTOPATHOLOGY (2007)
Siglecs and their roles in the immune system
Paul R. Crocker et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
BiTEs: bispecific antibody constructs with unique anti-tumor activity
E Wolf et al.
DRUG DISCOVERY TODAY (2005)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
T Dreier et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
A Löffler et al.
BLOOD (2000)
Share Paper
